Literature DB >> 33194059

Polymorphisms of xenobiotic-metabolizing and transporter genes, and the risk of gastric and colorectal cancer in an admixed population from the Brazilian Amazon.

Amanda Nazaré Cohen Lima de Castro1, Marianne Rodrigues Fernandes1, Darlen Cardoso de Carvalho1, Tatiane Piedade de Souza1, Juliana Carla Gomes Rodrigues1, Roberta Borges Andrade1, Antonio Andre Conde Modesto1,2, Sidney Santos1,2, Paulo Pimentel Assumpção1, Ney Pereira Carneiro Dos Santos1,2.   

Abstract

Colorectal (CRC) and gastric (GC) cancers are associated with increased morbidity and mortality. Single nucleotide polymorphisms (SNPs) of xenobiotic metabolism and transporter genes may play a role in the individual responses to exposure to substances implicated in susceptibility to cancer. The investigation of the genetic variation related to the activation and detoxification of xenobiotics may thus help to clarify the prevalence of neoplasms. We analyzed the role of 30 SNPs in xenobiotic-metabolizing and transporter genes in susceptibility to CRC and GC. The study included individuals diagnosed with CRC (n = 121) and GC (n = 95), and 141 controls (non-cancer patients) from the population of Belém, in the Brazilian Amazon. The results indicated an association between the polymorphisms rs2231142 (P = 0.013; OR = 3.01; 95% CI = 1.26-7.13), in the ABCG2 gene, and rs1801159 (P = 0.03; OR = 2.35; 95% CI = 1.14-5.05), in DPYD gene, with the risk of developing GC. The polymorphism rs17116806 of the DPYD gene was found to be associated with a lower risk of developing gastric (P≤0.0001; OR = 0.043; 95% CI = 0.015-0.12) or colorectal (P≤0.0001; OR = 0.076; 95% CI = 0.33-0.18) cancers, indicating that the same variant may play a similar role in different types of cancer tissue. Additionally, the carriers of the TT genotype of the polymorphism in the ABCB1 gene (rs1128503) presented a reduced probability of developing CRC (P = 0.0001; OR = 0.16; 95% CI = 0.06-0.41) as well as GC (P = 0.007; OR = 0.27; 95% CI = 0.1-0.7). Our findings indicate that polymorphisms in xenobiotic-metabolizing and transporter genes may modulate susceptibility to colorectal and gastric cancers. AJTR
Copyright © 2020.

Entities:  

Keywords:  Brazil; Xenobiotics; admixed; colorectal cancer; gastric cancer; polymorphism

Year:  2020        PMID: 33194059      PMCID: PMC7653561     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  45 in total

1.  Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract.

Authors:  Mari Thörn; Niklas Finnström; Stefan Lundgren; Anders Rane; Lars Lööf
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

2.  Assessing individual interethnic admixture and population substructure using a 48-insertion-deletion (INSEL) ancestry-informative marker (AIM) panel.

Authors:  Ney P C Santos; Elzemar M Ribeiro-Rodrigues; Andrea K C Ribeiro-Dos-Santos; Rui Pereira; Leonor Gusmão; António Amorim; Joáo F Guerreiro; Marco A Zago; Cecília Matte; Mara H Hutz; Sidney E B Santos
Journal:  Hum Mutat       Date:  2010-02       Impact factor: 4.878

3.  Pharmacogenomics and variations in the risk of toxicity during the consolidation/maintenance phases of the treatment of pediatric B-cell leukemia patients from an admixed population in the Brazilian Amazon.

Authors:  Darlen Cardoso de Carvalho; Alayde Vieira Wanderley; André Mauricio Ribeiro Dos Santos; Marianne Rodrigues Fernandes; Amanda de Nazaré Cohen Lima de Castro; Luciana Pereira Colares Leitão; João Augusto Nunes de Carvalho; Tatiane Piedade de Souza; André Salim Khayat; Sidney Emanuel Batista Dos Santos; Paulo Pimentel de Assumpção; Ney Pereira Carneiro Dos Santos
Journal:  Leuk Res       Date:  2018-09-15       Impact factor: 3.156

4.  Expression of ABCG2 and its significance in colorectal cancer.

Authors:  Hai Guang Liu; Yi Fei Pan; Jie You; Ou Chen Wang; Ka Te Huang; Xiao Hua Zhang
Journal:  Asian Pac J Cancer Prev       Date:  2010

5.  DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.

Authors:  L M Henricks; F L Opdam; J H Beijnen; A Cats; J H M Schellens
Journal:  Ann Oncol       Date:  2017-12-01       Impact factor: 32.976

6.  Functional analysis of SNPs variants of BCRP/ABCG2.

Authors:  Chihiro Kondo; Hiroshi Suzuki; Masaya Itoda; Shogo Ozawa; Jun-ichi Sawada; Daisuke Kobayashi; Ichiro Ieiri; Kazunori Mine; Kenji Ohtsubo; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

7.  Association of MDR1 gene polymorphisms with susceptibility to hepatocellular carcinoma in the Chinese population.

Authors:  Yong-Qiang Ren; Ju-Qiang Han; Jian-Biao Cao; Shao-Xiang Li; Gong-Ren Fan
Journal:  Asian Pac J Cancer Prev       Date:  2012

8.  ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer.

Authors:  Mariusz Panczyk; Ewa Balcerczak; Sylwester Piaskowski; Krzysztof Jamroziak; Grazyna Pasz-Walczak; Marek Mirowski
Journal:  Int J Colorectal Dis       Date:  2009-05-05       Impact factor: 2.571

9.  Association between polymorphisms of TAS2R16 and susceptibility to colorectal cancer.

Authors:  Jonathan Barontini; Marco Antinucci; Sergio Tofanelli; Maurizio Cammalleri; Massimo Dal Monte; Federica Gemignani; Pavel Vodicka; Roberto Marangoni; Ludmila Vodickova; Juozas Kupcinskas; Veronika Vymetalkova; Asta Forsti; Federico Canzian; Angelika Stein; Victor Moreno; Nicola Mastrodonato; Francesca Tavano; Anna Panza; Roberto Barale; Stefano Landi; Daniele Campa
Journal:  BMC Gastroenterol       Date:  2017-09-15       Impact factor: 3.067

10.  Association between single genetic polymorphisms of MDR1 gene and gastric cancer susceptibility in Chinese.

Authors:  Wen Qiao; Tao Wang; Li Zhang; Qing Tang; Dan Wang; Hongkun Sun
Journal:  Med Oncol       Date:  2013-06-26       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.